0001193125-22-019895.txt : 20220127 0001193125-22-019895.hdr.sgml : 20220127 20220127165304 ACCESSION NUMBER: 0001193125-22-019895 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220127 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220127 DATE AS OF CHANGE: 20220127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 22563843 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 8-K 1 d291411d8k.htm 8-K 8-K
0000885590 false 0000885590 2022-01-27 2022-01-27

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): January 27, 2022

 

 

Bausch Health Companies Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

British Columbia, Canada   001-14956   98-0448205

(State or Other Jurisdiction of

Incorporation or Organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

2150 St. Elzéar Blvd. West

Laval, Quebec

Canada H7L 4A8

(Address of Principal Executive Offices)(Zip Code)

514-744-6792

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Shares, No Par Value   BHC   New York Stock Exchange, Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01 Other Events.

Secured Notes Offering

On January 27, 2022, Bausch Health Companies Inc. (the “Company”) announced that it launched and priced an offering of $1.0 billion aggregate principal amount of new senior secured notes due 2027 (the “Notes”). The Notes will bear interest at a rate of 6.125% per year, and the offering price for the Notes was 100.000% of the principal amount thereof. The Notes will be offered in the United States to qualified institutional investors pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.

Closing of the Notes offering will not be conditioned upon completion of the initial public offering (“IPO”) of Bausch + Lomb Corporation (“Bausch + Lomb” and such offering, the “Bausch + Lomb IPO”), but if the Bausch + Lomb IPO does not occur on or prior to August 15, 2022, the Company will be required to redeem the Notes at such time at a redemption price equal to the issue price of the Notes plus accrued and unpaid interest.

The Company also issued press releases pursuant to Rule 135c under the Securities Act relating to the offering of the Notes. In accordance with Rule 135c(d) under the Securities Act, copies of the press releases are attached hereto as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, which are incorporated herein by reference.

The foregoing is qualified by reference to the press releases that are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, which are incorporated herein by reference.

This Current Report on Form 8-K and the press releases attached hereto as Exhibits 99.1 and 99.2 do not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. These securities will not be registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

 

Exhibit
Number		   

Description

99.1    Press release announcing the launch of the Notes offering, dated January 27, 2022
99.2    Press release announcing the pricing of the Notes offering, dated January 27, 2022
104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BAUSCH HEALTH COMPANIES INC.
By:  

/s/ Sam Eldessouky

  Name:   Sam Eldessouky
  Title:   Executive Vice President, Chief Financial Officer

Date: January 27, 2022

 EX-99.1 2 d291411dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

Investor Contact:    Media Contact:
Arthur Shannon    Lainie Keller
arthur.shannon@bauschhealth.com    lainie.keller@bauschhealth.com
(514) 856-3855    (908) 927-1198
(877) 281-6642 (toll free)   

BAUSCH HEALTH ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR SECURED NOTES

LAVAL, Quebec, Jan. 27, 2022 — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it has launched an offering of $1.0 billion aggregate principal amount of new senior secured notes due 2027 (the “Notes”). As previously announced, the Company is also seeking to refinance its existing credit agreement (the “Credit Agreement” and such refinancing, the “Credit Agreement Refinancing”). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the “New Term B Loans”) and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur upon completion of the initial public offering (“IPO”) of Bausch + Lomb Corporation (“Bausch + Lomb” and such offering, the “Bausch + Lomb IPO”) and a related debt financing by Bausch + Lomb (the “Bausch + Lomb Debt Financing”).

The proceeds from the offering of the Notes, along with the expected proceeds from the New Term B Loans, the Bausch + Lomb IPO and the repayment of an intercompany note owed to us by Bausch + Lomb (which repayment is expected to be funded by the Bausch + Lomb Debt Financing), are expected to be used to fund the Company’s previously announced conditional redemption in full of its outstanding 6.125% Senior Notes due 2025 (the “6.125% Notes due 2025”), refinance all of the existing Term B Loans, fund the Company’s previously announced conditional partial redemption of its outstanding 9.000% Senior Notes due 2025 (the “9.000% Notes due 2025 and, collectively with the 6.125% Senior Notes due 2025, the “Existing Notes”) and to pay related fees, premiums and expenses.

The Notes will be guaranteed by each of the Company’s subsidiaries that are guarantors under the Credit Agreement and existing senior notes and will be secured on a first priority basis by liens on the assets that secure the Credit Agreement and existing senior secured notes.

The Notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis, which is exempt from the prospectus requirements of such securities laws.

The redemption of the 6.125% Notes due 2025 is conditioned upon the completion of the Credit Agreement Refinancing (the “6.125% Notes Condition”). The Company intends to discharge the indenture governing the 6.125% Notes due 2025 concurrently with satisfying such 6.125% Notes Condition. The partial redemption of the 9.000% Notes due 2025 is conditioned upon the receipt of

aggregate gross proceeds from the Bausch + Lomb IPO, the Bausch + Lomb Debt Financing, the Credit Agreement Refinancing and the offering of the Notes of at least $7.0 billion (the “9.000% Notes Condition” and, together with the 6.125% Notes Condition, the “Conditions”). This announcement does not constitute an offer to purchase or the solicitation of an offer to sell the Existing Notes.

The foregoing transactions are subject to market and other conditions and are anticipated to close in the first quarter of 2022. However, there can be no assurance that the Company will be able to successfully complete the transactions, on the terms described above, or at all.

This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-looking Statements

This news release may contain forward-looking statements, including, but not limited to, our financing plans and the details thereof, including the proposed use of proceeds therefrom, whether the Conditions to the redemption of the Existing Notes will occur, the expected timing of the Credit Agreement Refinancing (including the New Term B Loans) and our ability to close such transaction, the offering of the Notes and the details thereof, the other expected effects of the Credit Agreement Refinancing, the timing expectations of the Bausch + Lomb IPO, the Bausch + Lomb Debt Financing, the IPO of our Solta aesthetic medical device business through Solta Medical Corporation and the Company’s plan to spinoff or separate its eye health business from the remainder of Bausch Health, subject to market conditions and regulatory, stock exchange and other necessary approvals, that the spinoff will occur following the expiry of customary lock-ups and the achievement of our target net leverage ratios, subject to receipt of shareholder and necessary approvals, the capitalization structure of such transaction, the anticipated dis-synergies resulting from such transaction (including the allocation thereof between the separated entity and the remainder of Bausch Health) and the Company’s plans and expectations for 2022 and beyond. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “predicts,” “goals,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” “commit,” “forecast,” “tracking,” or “continue” and variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results and events to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are

 

 

2 | Page

not limited to, the risks and uncertainties discussed in the Company’s most recent annual and quarterly reports and detailed from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission, including those identified in Bausch + Lomb’s filings relating to the Bausch + Lomb IPO, and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants), COVID-19 vaccine immunization rates, new lockdowns in certain countries the emergence of variant strains of COVID-19 and the potential effects of that pandemic, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease).

Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

###

 

 

3 | Page

EX-99.2 3 d291411dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

 

Investor Contact:    Media Contact:
Arthur Shannon    Lainie Keller
arthur.shannon@bauschhealth.com    lainie.keller@bauschhealth.com
(514) 856-3855    (908) 927-1198
(877) 281-6642 (toll free)   

BAUSCH HEALTH ANNOUNCES PRICING OF PRIVATE OFFERING OF SENIOR SECURED NOTES

LAVAL, Quebec, Jan. 27, 2022 — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it has priced its previously announced offering of $1.0 billion aggregate principal amount of 6.125% senior secured notes due 2027 (the “Notes”). The Notes will be sold to investors at a price of 100.000% of the principal amount thereof.

As previously announced, the Company is also seeking to refinance its existing credit agreement (the “Credit Agreement” and such refinancing, the “Credit Agreement Refinancing”). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the “New Term B Loans”) and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur upon completion of the initial public offering (“IPO”) of Bausch + Lomb Corporation (“Bausch + Lomb” and such offering, the “Bausch + Lomb IPO”) and a related debt financing by Bausch + Lomb (the “Bausch + Lomb Debt Financing”).

The proceeds from the offering of the Notes, along with the expected proceeds from the New Term B Loans, the Bausch + Lomb IPO and the repayment of an intercompany note owed to us by Bausch + Lomb (which repayment is expected to be funded by the Bausch + Lomb Debt Financing), are expected to be used to fund the Company’s previously announced conditional redemption in full of its outstanding 6.125% Senior Notes due 2025 (the “6.125% Notes due 2025”), refinance all of the existing Term B Loans, fund the Company’s previously announced conditional partial redemption of its outstanding 9.000% Senior Notes due 2025 (the “9.000% Notes due 2025 and, collectively with the 6.125% Senior Notes due 2025, the “Existing Notes”) and to pay related fees, premiums and expenses.

The Notes will be guaranteed by each of the Company’s subsidiaries that are guarantors under the Credit Agreement and existing senior notes and will be secured on a first priority basis by liens on the assets that secure the Credit Agreement and existing senior secured notes.

The Notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis, which is exempt from the prospectus requirements of such securities laws.

The redemption of the 6.125% Notes due 2025 is conditioned upon the completion of the Credit Agreement Refinancing (the “6.125% Notes Condition”). The Company intends to discharge the indenture governing the 6.125% Notes due 2025 concurrently with satisfying such 6.125% Notes Condition. The partial redemption of the 9.000% Notes due 2025 is conditioned upon the receipt of aggregate gross proceeds from the Bausch + Lomb IPO, the Bausch + Lomb Debt Financing, the Credit Agreement Refinancing and the offering of the Notes of at least $7.0 billion (the “9.000% Notes Condition” and, together with the 6.125% Notes Condition, the “Conditions”). This announcement does not constitute an offer to purchase or the solicitation of an offer to sell the Existing Notes.

This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-looking Statements

This news release may contain forward-looking statements, including, but not limited to, our financing plans and the details thereof, including the proposed use of proceeds therefrom, whether the Conditions to the redemption of the Existing Notes will occur, the expected timing of the Credit Agreement Refinancing (including the New Term B Loans) and our ability to close such transaction, the offering of the Notes and the details thereof, and our ability to close such offering, the other expected effects of the Credit Agreement Refinancing, the timing expectations of the Bausch + Lomb IPO, the Bausch + Lomb Debt Financing, the IPO of our Solta aesthetic medical device business through Solta Medical Corporation and the Company’s plan to spinoff or separate its eye health business from the remainder of Bausch Health, subject to market conditions and regulatory, stock exchange and other necessary approvals, that the spinoff will occur following the expiry of customary lock-ups and the achievement of our target net leverage ratios, subject to receipt of shareholder and necessary approvals, the capitalization structure of such transaction, the anticipated dis-synergies resulting from such transaction (including the allocation thereof between the separated entity and the remainder of Bausch Health) and the Company’s plans and expectations for 2022 and beyond. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “predicts,” “goals,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” “commit,” “forecast,” “tracking,” or “continue” and variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results and events to differ materially from those described in these forward-looking

 

 

2 | Page

statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company’s most recent annual and quarterly reports and detailed from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission, including those identified in Bausch + Lomb’s filings relating to the Bausch + Lomb IPO, and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants), COVID-19 vaccine immunization rates, new lockdowns in certain countries the emergence of variant strains of COVID-19 and the potential effects of that pandemic, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease).

Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

###

 

 

3 | Page

EX-101.SCH 4 bhc-20220127.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 bhc-20220127_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 6 bhc-20220127_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g291411g61r84.jpg GRAPHIC begin 644 g291411g61r84.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Jan. 27, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 27, 2022
Entity Registrant Name Bausch Health Companies Inc.
Entity Incorporation, State or Country Code A1
Entity File Number 001-14956
Entity Tax Identification Number 98-0448205
Entity Address, Address Line One 2150 St. Elzéar Blvd. West
Entity Address, City or Town Laval
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H7L 4A8
City Area Code 514
Local Phone Number 744-6792
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, No Par Value
Trading Symbol BHC
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000885590
Amendment Flag false
XML 9 d291411d8k_htm.xml IDEA: XBRL DOCUMENT 0000885590 2022-01-27 2022-01-27 0000885590 false 8-K 2022-01-27 Bausch Health Companies Inc. A1 001-14956 98-0448205 2150 St. Elzéar Blvd. West Laval QC CA H7L 4A8 514 744-6792 false false false false Common Shares, No Par Value BHC NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 122 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d291411d8k.htm bhc-20220127.xsd bhc-20220127_lab.xml bhc-20220127_pre.xml d291411dex991.htm d291411dex992.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d291411d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d291411d8k.htm" ] }, "labelLink": { "local": [ "bhc-20220127_lab.xml" ] }, "presentationLink": { "local": [ "bhc-20220127_pre.xml" ] }, "schema": { "local": [ "bhc-20220127.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bhc", "nsuri": "http://www.bauschhealth.com/20220127", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d291411d8k.htm", "contextRef": "duration_2022-01-27_to_2022-01-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d291411d8k.htm", "contextRef": "duration_2022-01-27_to_2022-01-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.bauschhealth.com//20220127/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-019895-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-019895-xbrl.zip M4$L#!!0 ( *&&.U1(UPI0# , H* 0 8FAC+3(P,C(P,3(W+GAS M9+U644_;,!!^1^(_W/*T24O<%! BHB T0$("A@I,>T-N'J&7U7T M!(X[D?VVK0JI@T%ĘD^XQZ7:Z73A*XL.D>P(/=W!%M4$EX(GEV(;*8J;8 M:&S@:_H-/.A2"H&)L">5V M(JE&UKMS0.QI&4-U&3-]!)@<>$)^+7PY:W%=AR MIB'5 Y^EL7B,RW)09:'&*#8H#5Y+E5_BD);<%E:*UY)R-F28>2_DF*,P2S[+ M'H:J$9I[FJ,N:(H?OV6=K3M^>Z(Q^7UW^^B%%)PY (#7%LL+J0Q4$KN5J5?^ MEEMW3V$CEM!MA7'7'D-D@P4@UC+?H#0@GR;2:/"?B,P%_!DBC5(=@Z--N==* M>^>L>@>M^V>]4^WK.N5#7#8TD%N&U7+K.:QIO3J]3TZ%D,9G;%.B1<'$4-9; M=M-=7M+<8!^'X*=+0E6J),?M,X@42A:H#+.-O!!!%6"L<-@+[(0-F_9ZX700 MV?9J/-[%7U:5,Q,+07Z[8-=@#3,.?.O,X.SV'X#R>6AW+;U V_/G+57^WVH+ MA1^MUD*TG6O^TC87_=#R^G#M+L^3]0"W>.[?;)^,\]%(#)U*(?-91?12IJ6; MP,WOAM>*=D-5KR^<'7X-IC&W#URG9'+IAMQM6[S:4U MC4Q6.[G>:7=\M56-'OOX%U!+ P04 " "AACM4Q-#QR'P& #B1@ % M &)H8RTR,#(R,#$R-U]L86(N>&ULS9S;;MM&$(;O ^0=INI- H22):<(+,0) M#-DNC#JQ$2MMT:((*'(E+4KM*$O*EMZ^NSS$E+2D2.^P- (D-#GSS_SR-\SR M8+__N%X$<,]DR%&<=OK=HPXPX:'/Q>RTLPH=-_0X[T 8N<)W Q3LM+-A8>?C MAY?49')A'T3(<]GH/#P]=?\I%B,$J4I)AU\-%#QPGBQ^-O\+O M2;DAO#OJJC_YHY*Y.@U\-V)#Z/<&[WJ#H\$ ?AGVWPX')W#["2[<,&)2P)@O M6#X5EQO)9_,(7GFO(4XZ1R%8$+ -7'+A"H^[ =QEC;V!*^%UX2P(X(M."^$+ M"YF\9WXW50VX^'>H_YJX(0-X^0) ?5@BC/>==K3EU/%Z(H,NRIGJ]>BXEZ5T M'C/6>RD/QW%"_^3DI!'W!2KQ/N]/S]=WWESMG =]2&K;XJ7E@GY,(SW M7Z,7?X05&H3""/V5DX4Y>I?3'SC'_>XZ]#L?=,'TTW$G++A66Q![&$H,6$EA M?3BNWDGCH\U2Q;-UQ(3/4N4?VNBE47/)IHFJ1BR6#)G7G>%]SV=< ]+__E9O M.LFF[O)G]>6W$2JRSR9A)%TOVJX9Z(\)9;8S-G+:,23UMIO2<6?2V])RI9?I MJ,T#GT$:T?-0?>^6D1,K9NE3B0MC%VDY-!S\%DP"8YN:)K6E!YD)Y^O=(:^) M4-Z89"&NI$*LSK:S^75M5I)&37=?NUQ_($=%) 7BL +J$-<_-]9W'N6[S5#"KJQ64 M2Y3QXOXN4@,TPI6(Y&:$?DVV#TBUBGHUFU@YQ7X0*LC3SL56P3<0EP24D)8% M79=H6/X';X;9L3-(-5"7/&"?5XL)D_6F)Y_7ZJ@8#*#YN/T0[&K1$J_5(9$G M INZ7P/%E9JF@G7LKJ]\M8CB4Y[DV= M[I,:Q&=ZRL9+3_.'NB?&^1;#R W^XLOZ]S7-"L\!;;,I$^!;D628&U0;@CVI M!*H4Y7W*YFR4H5_9"\&;*MJD9&X=Z+=SVGI/Q=0X[A^S>DME3X<(WG@)JY5I M6*7O<^L-E8K-VL.H7R$+;NX3- M])L'M4[3]K#^(7D4,3'"Q6(ETON/855B"Y);PK;<"I8$V0!<(DA$<5H!MDM8 MD]Q@XWFS3^JB4G(WJ,JS*;,EF$M,8%&$#<9%:D0,/\I# MIF\-<%,MY^FMU;<]NK>2Z3EA"HWX[4C]7K>\F4ZK+R+*%%I"N8(I/!1I@_8A M52+$51G'R]6!I!#$E:QA;]I$'OHG.B''_RH,5TS:#X%!YWF,0K%!\T#LQ1.. M18%V4\.1E&MT1AIR5#HIM6P1+'68MU+KJTU_,!GS**A\[V,_KZUE3I$!-!^W M6N(8M8@ CQ4!I] ?O)J\AJR6_2*GD:;S#-?NW![;L73U3TC>;183K+PXWTEJ M"5ASZV@X:(.J08B*TT09$FEK/!MH=(O-BMW2G4DOUMY<.69U?N3!G-OR&=5H M!(MC*,ZL^WI4EX]I <@JT/S(0W-];UU#UFR>ZHG@Q8+)F9J>7R4^1'.U,EJZ MHN9S[@*)5I\)EMO"@Z'V3P5+9(EX3Q^E984@J01I*:*G@@W:,#P6K.V%:@Q& M:ETNW>!*K=Z,@+>AI"8AK@"I"A'@CK1O@KM&_ M/=9GZDK3UU>;EX$[JXKS3E)+&)M;1\-!&VP-0D2X_E &+6T-:0.-YN$\T&U^ MQ[7:TK^T)=W%DU]=HO;\!U!+ P04 " "AACM4N!QM&[H$ !^+ % M &)H8RTR,#(R,#$R-U]P&ULU9KO;^(V&,??GW3_@Y>]V:2%$&C7%94[ M(=I.:/V!@-NFO3F9Y(%8AV4]Q*$!Q_'W_]?!S'F%Q] M7*<4/8&0A+.N%S::'@(6\9BP>==;2A_+B! /2859C"EGT/4V(+V/']Z_N_K. M]]'U[> !^2A1:B$[0;!:K1KQC##)Z5+ID+(1\31 OF_K]R>?T._;YCKHHMG0 M__FS K"1H1@KZ* P:%T$K6:KA5$O9W MQ[Q,L02$WK]#^D^GB\FLM.N93N_ZO)X*VN!BKMTVVX$5>7G-NB1:M3-)>'EY M&61GB_4EJ:JM&PB#/^_OQE$"*?9UJC6::*\I[296S^J\N?-@>]+6EZ0CLTAW M/,I2?T2WT,$:YI-OJ_FFR ];?CMLK&7L?3!-;K,J.(41S)!Y_S0:%-J"@JO.>/I)C"ZX)I'RQ28LN\]%M\P1=1FP&9@K0))T0<%#0:Y+"Z&'#U-9[3M=4!# M6@&+(;9AC/]OV.D/6[B[$YGB%Z4ZD$CE0Q%=0,&RYL(<53H%VO0A3\UZ9L!B;:Q[&>BIJBI3S GH@* M$;&(;#1]6*)7O AV-8(%%CJ>'R6$/H.?"9Y6IF?7&J_RR44,HNNU]%S9##VT M$(0+35R7>&@IM16^,*8Q->=@!D) ?+?M]$&3F4,]CTK(:GY#/D/0?O4@C:_U MG'XJJ#UQ_8GM&;;H0J?0;6>4$EU#1<+ M+K+TCG66H<^73(E-G\ .QBD[A0/&K=(SQU$VHMCG6BY>]/K?0A/PUD9 MH.XH*TU;C#^[B[&O#Q_%A*_8FR#FY8X@S%O. 6P["C"[MS^*H>!/Q&R&O(5B M*88C*$N^7WB&KO+<+=/>=C5:K2/\GOV^<&NYRFW(I<+T+[(X_:M&=01'&.ZY M?B'9=HBDN2?T!.!3V!4U]:55]+GCTW9K5\;LT--APMF)7_S*NOIR*GO-L0K= M8?6']JB ]7F:+MGN>X\\%M@!<7VI'3!LT;FUOS+FE$1$$3:_UPLK08R]X[A5 M*>L+K;6+LM0@!EZH%>_V8\FYJC M@91+$/^>9T4<9ZA6>+=LW=IQ&4.T-#;#UG1"%#UZB5G6U9==V:ME=>$4JXG MY@F@\2:=\J-O?WNB^E+:,VH1_>(4(CO4;M91@MD<3OF-MEI;7V#5?BVW2Z>X M;?<-;E(0OT;G(BQ)*X[P))AB\ZMW92>7ES%9H%U2_'\6&1[HOJBVC-J$?T/C[-"V7D?GI?-2<_3WZ<0G MMTPJ+H+CBE-O5@@+7.'Q8'1,^KK<=T5$P2FU71:^RDH MBIZ8#I MLKX.] U@O^S7=]>?L^ZZO'_6M:$E#=10R G50-V8'*V:T\I-4E.LB#AXKH_$ M[;WS.'NUYD%M-R,K+,[OV^H<%K'5RP;D.[]MV,:DJ\?F^B7P00/NR/F]G=)& MS7'ED*J!F3=I,0.0(S/0E=3+1J5-B\.6LS"*2<7("Z,>_M9<^^SDH/;IJ&$_ MPG<3IBG!&6KL]XC?'E=Z(M LT+4;6*Y"7/MT7-%LJAMF1M+ <8UX4D+(T4!X MLY,CC]\2I6<^.ZYX7(4^G74#$;#*"3GBTRYV9S+^S#V/!?8S=+F()DQREW#O MN/+1-/T&&/WM+ @9SU875+_//#8]!.;_>9%TI#^-Q0B(]'[OVF1>ZJ0@$X0 M!L:[I5/$FYKJ:S:$;BOG.VG"S\'!WEZG>=0H0+QJ!Z<3%GCP3W_PZ6@SR M# M-X9X2'W%%H%MS.%>LB&3H&*9@F?48EUE5 TL0XP"["+/'5<4GX0^2HSY;BP1 M"E!RM42/U:?*2UJI=*5 'EA;73Z"(CXY:A2W$V^^L&'SK$0D[:-1'-T8T8:2 M:R Z&<8,HZ6/W,,OAIQ)8D!@I6JM=_ZIR%SS@Q'JTOE#(*CPTD?0:%*_IYJ= M9+ E([.V#%9O2=^D)5TV7:=1P$Z*S0Q[C;R(-T 5P*^<0L!1->KS4=!U82], M5HKM=]S3X^Y!?8\'A[F^/AOJPPF5(Q[4\'.7T$B+Y!O)1^/X*YPN3";#PZ(V M9J85K(@PG4*+L)M[' BMQ<1\,Q 20$^^<<(I4<+G'GG5-#^5DY]>.6^;AT>- M<-E"NZL7:GWS0KEIVS )6=P &0)I:HK_P;K.0?H\I!/NS[HW?,(4N6!WY%I, M:'!HVNXLW /A>X>^%& M>.;E3(_USSQCUA1/O!=.>!1.V(KL@G:Y/KNX(==G5Y?7-\^O2ZXBJ2(::*(% MZ3,7F8TXNT1(XNSM>&^>'T Q)'K,$+9(09H6<4S BF-&&WT)M(TX5Y;[JKE<*5L47.K(FRJ78@ MUF4\KH";V?5@@MH$QH]QE9I'9[49 %9C0>7DGS2(J)R1UGZ5X/@7E?(4*J75 MW@;CS;'0AAPR[S5>LQ%7&&[0%]!2.7EGHCCDHPGCD)Z8A#1 *3P/W/H*+ME, M6S2W@8N=LRD%K8"@6UE,-D.H(OV0N>A@>(0'Y%PKTAN#D\#DO)9[X>XEW/T0 MQ& ESS':\5[=87OTU"Q;O+A?A[),10:;A8; M3K/Y.L9=MQF#V6TF#A0")NTOK^B7[;9?HTNM;1 I;;QE4G.7^C%R[7[+.L:S MM-:?)0&X=,3\=/!?#+=,NH1TQ&H#R>A7#)N"1]VEMP*X8VVD.89LA65)CI%( M@9.ZAH?(W$Z '0! H'!08)NV/E,D C#?_?M' MZ@?N,YAJ@%JK"7V<=F?O[:+"_ZN@XX9.S^, E6O&)KCI'-2:[?8!N.#W(>?U5OSB'2.MZ&U<@IDLR3_!QE<>MVZ(&)I#:$WPG$< KZ!8#)1R M!-;/'^;YC3TBGX7SGY-D8 ).N,)DY7.3!U44L7+X5R7&>?VZWJ^3LTGHBQF3 MSTV1HHIWXBIL]WPX]3S)E(I_?0;;WJF_,*6_/_?I47#2@X^7\D;<@9WUF=Y2?]&X>I1US=ER M*:_ TN,F\SUO""KL@(8@3H!6X/]$;,#<[YXLR_!LS=F'Q(@,6F*S.$%*8OC> MGP)> M.5 "3[_\=#:XIO&-O^N/_9JNKVZ<$VJ;(=W1MO$>,,5Q(XC(?4)V=3 MYD::WS)R.00]R-2;'=@]P>W?$TQ]+J6740V%]!2,T6^BTY[3GB=/;>E*GP4< MH%=C$23NQ::K[;?;M;?[G54QRF?@B"S<]-.K@Y:S?ZC HO!9B)LE@=EME0"G M^!%&.P@%?,/F'\H9VX'] V@!L, #$SF31BG ([4\#E /B8VZ@[&$VI3X5"6! M[)?XV>,DG%9)/.CF,7._F@P##>$@"R5'=VH@IF3 ?'&'5,-&I"TYJ'TB0^XC MXW$%7*A9X $UM0""3B)?TX")2/DSHD U7!F1L8#Q #P$'M!=DJ9158CF %YSGA(I$IP\^.R;*YZIG,3; _SD]T?"7+KS.@(>:K?V8@:>RS)B M]#]>DM=NL0\!@L'H"ZA"T(?^C\/3V=Y@:KNY M189VVK3FM'(\74B7IQS=;M9MSQ>F_OZ9^DHRU--8P6GJA/#DEN!?H/'\HS W M[+'FYC:Y4G,[;:_6VAF\68_5;=\79O_3,?NY4A&3+RQO6'Z7U=H[[GHL'_=] M^N@K'%29&67]!";!TPC+2LV,!,=^ VQAN9OP4G'P8U8QURS M&K(" \UP)^D&Z9O'2)?HILHYP_8"7%%)_D7]:.&:W9^H%"A#4*Q1K$1OC)UW'WL_ M!!82-DEL25/X^] L(LI\DD)$X?A?(;^2OA;NU]1F7R5E&F2 ,)7"W#CC=E[KX@3 MLY8_P\7O."R-] @ /FB1[)8K& ?L3 ,78Y#4-24#V!E?,N!1Z2F;^O&6N7V[ M.S1U^_)\6B74OS1;LC:O.)\=O%O.7-EP("&8*[X=W2F_A:SZS@U;,"S M%;+[JF-^#A,XPVDAQ-1XQJO,CUQC P*FV<0B]*#>=.+JTS.\G*7N48!OE\"2 MWU_[]8:ROGAJF\]=K@&#;AQ, 3FZ$!H&FA 82EIZ*&X*K"$.:!#8Z^; 7@8D MOBIFL9?<%ZN2^^X)D1V4+FJB,86#5!.?PO,8 MO@!= GJ$N^8CJ(MXZZ W_@O$UT(PX+Z/*H6.1J#X4"F&:3$.G:!>POZHNQ0+ M..@O%>,S,/CT(H8;V"^ :%"= %@G-]!BL7\'BY$! QL8\^<2;_0!R)3(^*[? M6SA4]UZC'B5XM:YJ=H 3I[";[1@-J[-904N#S(%GUWR=*,6%32"',C$L@<9. M;DT+'/ISP%'?F_(WA5KW]P@X*;[WI. LC% 'P\P\N(4="%D:7&^?+L^+QA9* M%>T:.K''2!Y_Q>X)(BTV1*31E2J'M" +9=$:.(-K/]?[]9C[$=-J(53*1I%O MBQ7Z2_=PGYG3>@S)Z?E"Q.8\!M1$H0CL6S?P/0$=DT.S$!SJ\N4_F"(;%L_C?Y+"8#D,VLICT94.@1#S7D4A%\G2+E>XHM[I*U@@5^,37*(!:DTD&L@0RRBT&426C/'R"!#L<#!!J&898@; M"A0*_4BA@2.C6!]%04BYE\K_D_/130X5U%?"@HYZ$FL1)5A[5+'2W,&>NURB M81PU!ER,C[RN39%1!V5NC#WIX:NDK&683K[CO5DZ?Q5X..2&X6/M5@"62B22 MID;IHYX#*"@Z,&,^X%J13J?N&.3#AY8%$3R67B0E9DWB"]= 6%/GM%*''-0^ M51/]8<-!N#Y/[WK$,( V!?,Z?77.LQ :K;B1B$NV,C6>ARNAV!Q*S5E:P.L+ M0A^XQV2+R9D^S\1K,[ GC/X#/6]/8Y9:-Z8:CX%^B^T#92L^TLJ[?+]!9$KT MP)U3J:Q586*P<,;@P%J# 16EK+DFXW.:P)8:F9C\_#RR H1>OBHLA M093(S5<%+IHERR1V$H()7D"YO<2F+@MU07^B*SY-#H^A%)."FVV^C0\CS.*J M)6$=)#\-0T!77"-0LI&\=3>FMRR&G 5F=!YEF3(8)EA/%(&U"4#4P 57(7C< M<(+%-9K9\J:JGR//EZ'2*GG0._ZLFO&/-0@REIEC&'M1(#V?)Q2L/#3,R8 J MD#S+.US%N,P0F0-S'HV&T^9Q].(";]D%[J +_"$-YQA!L"1 @B=*[(D]330G MEBR=FZ?UW1<%F*UN6A5@8]UD[?3]7I*A+RLJZ#Q^_IX\9P+__JQ'S$-' PGB M;&^0H$,CBNM1W_!Q;U4!PR7,AH:<5OCF=+\'27V):->J^.T'<=CTT['J8_U MQ-2*9<9F$C,S#MN8Q0&S\M!"E7C& B\-VY&C!GVA*]CD3T_7UAITQ7C$TIC1 M"V%7$=9IMA^5KFBKNP):".XR,6BWY$C;Q*2.7U9EW@1.\%7@]0S321;\Q1A^ MA)NR?7B@.@+Q?.HX1?Z5C-;1O->W+$OS5\L2P5[DSXA+(V52+5S%MS=-+ %\ M.=@O^L;@Y\,R S:F_A"=2)S(>(]Q!XPJ1%BC8:8#2HV%A(UY\^&;XFL5WY;-Y[2V/.%^Y_%?(+92=V9GQ]Y*"_[=Z<_] MWD?R\>ST\\U'?!'SU>D%OI_Y_*)77_&.I75..F3/^XXZTY[!VWY^Y)V\FW4W M/=CR_=.][%96<%/)&;691[*BJF%#S=A0#=*G$W+F>V UB>CK[ G*-]>P[QY MB\TL&JS,>Q#I-R;W/+K_,J@V!;-/B^OLW2'_PCPDN@;FCR)426_,V3 7HK/O M%I'+3,$-K96-9!!?0]PM=SKF [-'#?L74LS?3SGY?U!+ P04 " "AACM4 M@^IU5^$0 S. $0 &0R.3$T,3%D97@Y.3$N:'1M[5M;<]M&LGYG%?_# ME)QL675(2I0MZV)9M91$6SI'D7PDVMGLVQ 8DA/C%@P@AEOGQY^O>P8@ %YL M;QSO/JP?(@F82W=/]]=?]R!GUZ.?;L_/KH>#J_-VZVQT,[H=G@__UCTYZ?7/ M]NR?>+[G!HBSB_NK7\3%N\O[V_N'-SL_7]^,ACOGHMW"H$L592H]/[NZ^2@> M1[_<#M_LS+6?S4Z/>XG/1?]OO35_WT^&7OUV1*$T9O=F[OW]U; MDWTSL06=]N#B=B@NA[>WC^\'ES=W[][L[._PW^\'5U?%WS_?7(VNW^ST]_=_ MW!$7]P]7PP=^[F2P3[IPB-O!^\?A:?'+UB-JGF=I&(]]R%J&17PX=[]<%8(< M'?Z(,]T;72W??'2SK:I+D8N!=IC]'?]YJ"Q?J)'(J>J.4R4_=75DM*].Y5.L M??%U:IPW!,)1L/_=1$_*9'$J+C%>>MFI]<%2M*8&[J"*XUH=5RS\D_*U7%V5 ME?QN"@[2;):GXG$FHRB._K!:MU)'6HG_44&@TG^!.F.HWB>2HQ[/CP5??%\>'AV1Z-_./F>'ZR?_P%VYX<''7[_9/CZK;?V3[' M1T=?(.C!<;_[ZM7+ R>H>)[%02 FJ5*[?]QU*D"&'P3CY^O3Z<'+;YA/"W & M[EP,/CQ>7@O0@MO1M1CB_NWXOW#S/P[N8>9S2\_/ PO!)W]R-,*=+QAD3*F>V/:G!^.X !.^)_I( I45PF(A M9)E,PT62?!QH;^E;SHEOWM\7HF*"<^G_@@[A&&>>)G$J>;6ZS]L!S4,KUN83 M*TZZOF1E.[8,S!!(4L-78YB@U'"\:,A2,77]Q15-?+OB! VV_,U!AQQ:G:NA2Q)SA'40,C&>S36PA9Z6A[>R@FCZD?7^%2.R]3)V]$0NV$'( M?R,<-SS4<\%*D2_BN?62W*RQ*K(71UNQ2,.SQDI,\LC''^/%&D'(]NU6:?Q= M*)JJY@*YL;_20E4HH:-Z]7H]YE!0POWA>/!<1((*$_9"'6$9I%+H2E@3YYG) M8 DR^*M>_^#P1_%HL>^NBGF'5>]QX^H#G-MT*E@F[3;VN!RDU0ZFW?JG-4K M,75=LS4:G?3V47=]7B,WKC$ BW2P*=BEE^DGPK/2_;:9JHJVPT+O:IZ@A=LM MG"=B2(OA]ZASD/#SDE>$!EEOD\H6B7FP%9RN6DN4XE L'ZK)&/3NI,R M^1@$4=;T_^IW*IA>VQ+ M.H.?0"Q%@BP-^$BB(0(P=N Q7/5/7KP 9,!>T(= IN+4]=%E?$)% C;$2.9, M:\<$&PF"P/L\2!3^!!ZW] 0L331UH"6X\-V=)*['(=;T)D E3 MC@,"@"),&:=K@S*VX<(9 I^%1JP%L@BL1/; !G M4O"B)V6#$^O\ELM 3S2O!!_)<@<^XWR!R> #J<< M<6F#"7F!A)K8A99T= BQAQQL*&'E1;17#NU21A+P$#7/S:*K]+PX):@.%AUV M2SXZRX=HJRH'H./DU61YT*&$+1D6& Y/)4N4IG62$;06V[UW=?$0-[1KPW-JDMD$"P%D$JG[T M*EPY>7I4:9B,%0)%G&6K%GUZC9;_X.'WJQ4RS)%P"GST[X7Z-)[-H% ME\.[T?#AW^YV (LOR^ K9'L=!Z^7'9W/NV]!V-=6"$S>,Q$ S3/Q MPU&SY*]6SC6':;B^A:4LGBI,2%<(7V-.K; N'II*$%&M[_@KJ^/'F$[(2B4S M9Q15MBLX*>4IXLNHH@N"K*L]GFQ MZDS^0 E_!=22C-CIDW*ICPU:QJ2E>#0HR X;'ZLX,$L8TIB\$UC\I2K#R9_U;Y+D30X+9']AMIR1F)EVVW^"3[&=?ZH]?, [LR3+04I8.MD^=(/9$Z9AH MB., E>0,Q\";=NM7/#"^]HJBUF;^91.ETY#!<9=YG(/'4DT=(S65:FV!^+QM_"(LXOSP1B5NW MM]UJMGL)!L4TB,=(X$5G93ZC. _AN'R"3"]TB%P".IJH&-%8E)@!BF]CH3C. M4V&O>!#T*=,Z/_(WYS1Q2]12""NI^Q0"4A,"&H- M1N_) #.0=O ++:$].^FS;-P.:+>V#"%6U(7/=#UJ+M-UG+MVQF MBW;7%J>W4]>N(*T1 MW>Q_FN]2'QIKD.:/<9!)(97!3K1$>S'*5&AK"(BS]=.);J4F[5;):5'P2PUY\#E)<>UPZ)5PM>@>:EM M2L0IJGR3Q=XG6!$\E\!X20TC171,I@M[B?0D V[=.Q972+UT1X1<$,3SPJ=P M+CJE!H+PNFR!E\%B^<:8W8[6 C_5$,RDL<9?A>:J@M@RXN2DTIO.M/7*=E,9L MTK;^R,R(IM:?>:N/YJN/H'-C#.+%/2GJ7]?F;&H&T ]7%4Z K!%U7NJ/;3 T M)21>47]&9:('JM*8G4J/3JMXBH,MEL!>4:XJ]Z)/X$4%V@*Q ,*!9!R' QM; MH=&P9)8B)=LQ2Q>P'PAX*N4<799TT)Z;?ZF+ O85NNLA>PIK?7I;EHP6#?R. MC>XGVQ+/Y"<5E<,L)I5+6JD*<3F(*S+;+P" M6)I:8] VVMJM6@#9N,'A3SAS@=8 P\J+$,>GG[3OFKVVR9L2P7#< N^X$>.7 M]W 52:DB!KLI5%V_K32/7<=N@+IC6K&L.M$,V8FY QL#9]P#7R>QB;C)&4D2>B MF*)%7)LOH$MQD%D789;,$R1Q.$$R+EWHY_K5+2Y,4$=$4]LVX/QN_8ZNS^QO ME588;3,L".DE93%&Z7JQQ5W))8' WBM?\M#NQ;Y\K^\^[]I0(I3LI[@BJW;G M?!0;MAT5I^7%UB:#$PA 5E<#0#HB:)!PO*!BE2Y#,9QA9>$R3Q-"FL>[:2<& M0J9/G.GJ.I;?8WV6D5[>?[RYZO9/RDX(=E*A]JQ?391,;6D% *Z_DD]PAJ)( M9 #F.@XIF8LC3'J2GD?%"V>"KY>DPGJYXP2P3XI\89,J:3[)F9XS-P%B[W:^ M?B,GI]!AF$<%\T^9@/$GB%2:^/$\XI9GD:JXC^0^M8"]0U!Z.EJK-\O2;I'3 M:%N;?K50A4N6K*]>)Z\J3Z=>33BTGZG8-V7'&V&9(((+[V* MQWMT2<))WE%IHEI\$\WSB 3P-;4LTRMUHL AEGM$EL0[+*B&[FK+A&21 OE*5?'>SP6PZ& ME)55+MB*A^>ND\#-3U<76[6!@Z;X@HR4A-#4ZU.[CB?!J_.RA3FE0WT.")\M M+8I)[9:OW*P__PKB82UU(^O2Y54 UZ)&>4Y57Z#Y&H957;A&R1?1GBT$#J$H M/]DO.*3A*UQN]Q CM"5IK]$)YZX]\72Z=1/Q& G3E; QR#)/_$+IW&>Z]"U8 MI7SP=.KE(7UOYA$,3S+79^.5>=7FE4UQUV!7L&(I2I0MZV)9L;K0EF;5DE>BW=/[5@2*9+5!%!H%B,V)_?@]F54 M 9"4Y&W;NP_3#V,*J$MF5N;)DUF8X\O!+]-C=/=YV?^+YMA\@CL]N+WX39Q_.;Z]O[]YM_'IY->AOG(AV"X/.59RI].3X MXNJSN!_\=MU_MS'3838Y.NCNZ7A#R$B/XW<;D1IE&[S6QV+85*9C'6]E)CG: M2;*WPO\]-%EFIN[1R,39EM7_5$>]Q=\C.=71_&B@I\J*&S43=V8JL=/I]=6' MFW<;J1Y/L-7QV4G_SXD>ZDR06N)X^^SD>/OC246 RNJ[6+TASY(X&R=_BX4NK0/%U>BS/:TA&9L/\JU\^B/N[\W<;X]W#WNM>;_RFEQZ\[OZ>C&G"X-W& M]>V'6V>R;R:VH-,^/;ONB_/^]?7]Q]/SJYL/[S9V-OCOCZ<7%\7?OUY=#"[? M;?1V=G[>$&>W=Q?].W[N97!/MN 0UZ[$ M_[@H!-G?^QEGNCVX6+SY[&<[51I<=(0"$?!_G<5/RB;F52<8[P,LB/G@Z5H30W\017'M3RN6/@7 M%6JYO"HK^<,4/$VS29Z*^XF,8Q/_9;6NI8ZU$O^AHDBE_P?J''\ZD:Q1USJ- M_GTH[_6F.'Y_>S,H M87RB,[5E$QFHH]C,4HEA!WMOMEX=[.T=;]/(OVZ.EX<[!\_8]G!W?ZO7.SRH M;ON#[7.PO_\,07EMOWKS>]8**EYF)(C%*E=K\ZZY3 3+\0S!^LCJ=[K[^ MAOFT &?@SMGII_OS2P%:<#VX%*?;L[[]^+CW14E$G'[GGY^/AWT\?-] M_\X_N^_?7-WBD/KGG^[Z%^+F=H Y13Y>DTDYM?U5%4ZN3V'!COC/7 U5T!%_ MEW%7[.YWQ.[.[J[XVXO>7N^M.., %)<<@0#5:2(1GE9G3P5@#GLXD2;H!;9NY>;0H"E#P.5"@R$\HY!LJL MW0(UF4@KDE33&YW13_6@36ZC>66*&8U4JN,Q?HB?>MT=YR9#'47:Q$*.QZD: MRTS1.G&@$QD).<74C,:_Z?9V]WX65L4:\ED5Y"E6C$T&!<-B_M0VHS(V0<"IL'DW:K6!,+=<3Z>>)N,:YV"*5,H5B:HTG( M1 49>Y<(#)#/\N'+)$G-GWH*YX %?MKM[M5=A\Y(I5-Q)B(C8UOS ]AQX-Y= MT[N%(XFX4Y)/HQTL(@-'YA7'V\+43'!A^F_08?I$&>>)B:5O%H]CMV MQJF5:U=/K+YB9386F'SE;+EF1S9>QHR=RS@Y" M_AOCN.&A@0]6@BUA9LY+A:*J: M\W/K?M(Z#&:B O5OWJZ!< 0EW!^.!\]%)*AIPEZH8ZP#8(6NA#4FSVP&2Y#% M/7#?.^"^J0+V7M5[_+CZ .\VG0J62;<-32PAK7XPI)%XID+M5E6C!,19US5; MH=&A2PQ/:N3'-09@D0[,",H<9/J!\*SPOT=-58W=?J%W-=,>Y3"4"P?FMDHQ-JX[*YD.P7BU3XB_$ M,=B#_71*UN3\CJ8L ;+3TEO(\P7'$^@-B=)N$0'P%(*8!P N1:9!CCN,#^!^AAB*1)D8TJQEC(O5)>$R.0*?I4:L%;((O$O]@ SJ3@10\E[OZ1RTB/-"\$ M%\ERCSW#?(ZYH .IS>'D-/HNAWR]UZ]/UY\6*4/8A!)Q62K NGFZTHM-O/6I M>]\M*KU"A9HD:IQ'SK#W:X6I&FTB'Y0_XP,(&(_(""36Q"=-LQX80 M>DC!EA)67@1[YY>O$[8NKSZ@9 M?<>9>WE4)R=PQGFDZGB@IDMP0(\J'8*A@A75D8QF.P):U M^1@N;U?PXR4FO(H@UWEI9W7ZK!Y#P:97\G<6+!,1H#83/^TW^PEKF%B[U3A# MQ\@R,U94T2^QL8:-:U5O\;#::*!"W+-+5B^)Z& 7K&:$="1P15%VE"YHM?F5#(M M):Y7>\'CB4@K3P?ZIEX0[.I0!>(C/%!4, MUS&_^1U_VU '1>7CTL.BTNXT1/ 9;F9RL!VJO&(D Y1+CF^Z3DV=YOC\H MS%*Z,R,D.Y*5]JZ*]2C#//@6#G%\=G(Z!/-H=!U77$Y6MG[S+79V&[9;S^MS M4CB*<62&0,2B_)Y-#!QX"L?E$V2\UE-@&CA+H@P215&'1*C0K(,$DZ?"76Z( M@(H1# _S($/P_:I$"((7F:0#Y>)\) .&>L=[TR^*&HLH7,;L3PFRPA3\"[PO MD!%F /[P@Y:@UJ.D:OQ)SO;D ,HR6W"9K8":E70/Y>\;/,?SPE-QJ"$C#%WP M6@H"F;!X5'1)AEDU5U[YCA@#;E/#[,!$9CQG/>&A4YGQWVP0LE"HR'P.MF.V M'PY@JC/'D;#P#,&6:P2%C-LM#=!\D%02E^<4LFE\RT*&#SXI^-/T-TT_PM/? MFW0FTW K,H:;JTROG1I/=/^_B<$#PTH&N86QTK2\JG)A]/ MW 3QBQ]5[5K+-1TZ>"#G_43', VG3@4^2\23[S!*&%IL5C)0%%]2T0.%NY(PJ2NP#4I*D:;F> +K A:1IC-)T@GTV[%8,36RG3N M;B0>9,1]8)!0SLY>ZH7;(C:CR,P*Y\/!Z)2J41'DV&1*"SV)Y!&$VU1+FT9>>Q E"J4M54V3QB/.!# M;F[3C&U0..,IDP\_L*UL1@T(1YZ<)R&P(%DVK[3JUSG.)M&KM9ZZ:*B6T4;M M#+Z2I3=#-8>3=44S>RP FG%\K* V9*=.D=!4)[K6B._L>WBEGS.3 E]=[;&P MKNWX.L:]]K]H$/?.70=PY2(B*<@>,=]@["\TZD(BFCFDJ50=?6^+AW( MD+JQM&,@<]\9*9#>JF8,^[XF@V9"SL#6\ G=2VB?::<*4A=N@<+NBQ.,V@K\ M+"MO1M@G2$I+;I#EW/IQ/L/XQ)[$K>!0X5 M@OH/+\5Q\MPO1D65Z1XT/N%<$.8(J7QKHNBKTJ->M[+2ZH6IHS$$%J+$\4]Z MR9]<=(?BQ0[_]\Q/7+]%<; K_IN* /&1TJTWT;]ZO%]IQW9K$05%G*SS>I?U ME2MI*&*:90TG]363J2^;6[NXQVDD]JFQ&6,H8TY,T42+_)'+%*:*Z&X5+-;' MEF/[!$:((X08M.+BAOY=O;Q#A!%J@7ALRUZC\U6ZA'&_*KTRVJ9?4-%SRE\, MS_5RC.*WPARP]=+W(+1YL2U?#_N/A-84!R7M*6Y:JNV[$&6&ZU>9U';:+?^Q MPAJ+TPE!6,_^(1YQ,X@X)%O2E1I&\Y'/?I MZ/GMYZN+K=YAV2O!3FJJ ^=7(R53Q\?HP[?Z._D ;R@*/<9>KN"0C;E2P:P' M&014MG!V^&I)*GR7/0!I^"S-/9.KU9&"H;,))-\=5"%2Y9\KUZ M@8Q,6#\-2R403J(CPKQ2=GKS:(2EN^UVWDN.-D$"0H277L7C ^KFN^MSSZ*) M9?&-)D^D],^WG;),K-2K GM8;%*#@FKH+C=EN,ZU>9) $$2]YF)*(PG3M<[< MO=%8G#IWAGF"[STR2R+DH61*#'*:1&:N'._J8(<_ZH MKXB=VL!!Z[]#:K=(24A-[4"UZ1D2O#HOFYQC.M67@/_)PJ0T*51^TO?_YN%N M)6I/E3(A/[V^'5?&=53GJ$NR$6Y1?W(8 L^RXA4<'B M0]%ZJYS;^L30Z7I(F"%RK2]>#5@R3WQ,NEH-P1][TA=%E<(AT&F03^FKI8!0 M>)3Y1AROS*LVNXK&7:842WDR"<:,NHE<*H\CPC%_U,C_![K_ 5!+ 0(4 Q0 ( *&&.U1(UPI0# , M H* 0 " 0 !B:&,M,C R,C Q,C'-D4$L! A0# M% @ H88[5,30\&UL4$L! A0#% @ H88[5+@<;1NZ! ?BP !0 M ( !Z D &)H8RTR,#(R,#$R-U]P&UL4$L! A0#% M @ H88[5.8=?,(=$0 Z&@ X ( !U X &0R.3$T,3%D M.&LN:'1M4$L! A0#% @ H88[5(/J=5?A$ ,S@ !$ M ( !'2 &0R.3$T,3%D97@Y.3$N:'1M4$L! A0#% @ H88[5/$1$-2E M$ 1S< !$ ( !+3$ &0R.3$T,3%D97@Y.3(N:'1M4$L% 3!@ & 8 ? $ %" $! end